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This is the first themed issue on new developments in opioid
pharmacology published by British Journal of Pharmacology
(BJP). It is a bumper issue, with 39 papers, including 17
topical reviews. The issue emerged from invited review sub-
missions by speakers at the International Narcotics Research
Conference (INRC) held in Cairns, Australia from 14–18 July
2013, along with open submissions from attendees, and arti-
cles freely submitted following a call for papers. The meeting
was sponsored in part by BJP and the British Pharmacological
Society. INRC has been the major international meeting
on opioid research for more than 40 years (see http://www
.inrcworld.org/history.htm). Invited presentations at the
2013 meeting were largely focused on novel mechanisms of
opioid receptor function and systems that are developing
novel therapeutic avenues that could improve the clinical
profile of opioids. In their International Union of Basic and
Clinical Pharmacology (IUPHAR) review, Cox et al. (2015)
discuss nomenclature recommendations for opioid receptors.
Most papers in the themed issue conform to these recom-
mendations.
It is very difficult to separate therapeutic actions of
opioids such as analgesia from serious adverse effects includ-
ing (potentially lethal) respiratory depression, constipation,
somnolence, tolerance and addiction because most are medi-
ated by the opioid μ-receptor (MOPr). The developments
discussed in the themed issue explore current knowledge of
new pharmacological understanding of MOPr and its inter-
actions other opioid receptors that could be exploited in
future drug development to reduce these adverse effects. In its
current state, the opioid therapeutic armamentarium has
only just begun to exploit novel pharmacological mecha-
nisms such as hetero-oligomer formation, ligand bias, allos-
tery and synergy with other receptor systems, including other
opioid receptors.
The INRC meeting was opened with the traditional
Founders Lecture delivered by Graeme Henderson
(Henderson, 2015). The Founders Lecture honours the con-
tributions of individuals who have a made a sustained and
substantial contribution to the science upon which the
conference is based. Graeme is certainly one of those. Graeme
was the first to show in 1980 that opioids directly inhibit CNS
neurons via hyperpolarization (Pepper and Henderson, 1980)
which was later shown to be due to potassium channel acti-
vation. At the time of his seminal work, the predominant
thinking was that morphine acted much like a local anaes-
thetic, simply blocking nerve conduction. His review reflects
the progress made since then and the unanswered questions
from an electrophysiologist’s perspective.
A potential opportunity to exploit functional selectivity is
development of heteromer selective opioids. Since the
ground-breaking work of Lakshmi Devi suggesting that dif-
ferent opioid receptor types can form heteromers in heterolo-
gous expression systems there has been an extensive search
for their presence and function in the central nervous system.
The review by Massotte (2015) critically evaluates the evi-
dence required to establish existence of heteromers in vivo.
One of the crucial pieces of evidence is co-expression of the
potential partner GPCRs in the same neuron. Massotte (2015)
appraises the evidence for this and introduces her own
studies of co-localization of MOPr and the opioid δ-receptor
(DOPr) using knock-in mice that express both MOPr fused
with a red fluorescent protein (mCherry) and DOPr fused
with eGFP. The restricted colocalization in the CNS suggests
potential for opioid drugs that selectively target MOPr-DOPr
heteromers, moreover the general expression in lower brain
regions involved in nociception indicates the potential for
heteromer selective analgesics. Of course co-localization does
not establish the existence of functional heteromers. Mas-
sotte discusses this and the review by Gendron et al. (2015)
also touches on the question. The review by Fujita et al.
(2015) further discusses the evidence for potential heteromer
formation among opioid receptors or between opioid recep-
tors and other GPCRs, revealing extensive potential for het-
eromer formation.
Multiple opioid receptors expressed in a single cell may
interact as heterodimers or, alternatively, modulate the
surface expression and function of the other partner. Zhang
et al. (2015) review the evidence that MOPr and DOPr
interact in small dorsal root ganglion neurons and that the
interaction is modulated by neuronal activity and morphine
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tolerance. This may begin to explain the widely published
findings that DOPr antagonists can suppress morphine
antinociceptive tolerance. Other reviews (e.g. Gendron et al.,
2015) and research papers, e.g. Ong et al. (2015) also address
this theme.
Biased signaling and allostery have emerged as proper-
ties of many GPCRs that may provide opportunities to limit
side effects. Biased opioid agonists that select for G-protein
signaling in preference to β-arrestin pathways are in clinical
development as analgesics with reduced side effects. Based
on the plenary lecture from Arthur Christopoulos on bias
and allostery, Thompson et al. (2015) provide an introduc-
tion to mechanisms of bias at opioid receptors focusing on
MOPr with a detail review of the issues that must be con-
sidered in quantification of bias. The DOPr is also a poten-
tial target for pain management, particularly in neuropathic
pain. Gendron et al. (2015) have comprehensively reviewed
evidence for physiological functions of DOPr, including its
potential for biased signaling, as well as the role of traffick-
ing and surface expression of the receptor and potential
interacting proteins involved in its regulation. Charfi et al.
(2015) review different approaches to identify and quantify
ligand-dependent bias at DOPr and review different
types of experimental and analytical confounds in these
analyses.
Allosteric modulators have been reported for a range of
GPCRs but until very recently none were known for opioid
receptors. Burford et al. (2015) review the principles of posi-
tive, negative and ‘silent’ (neutral antagonists at the allosteric
site) allosteric modulation in the context of their exciting
recent discovery of allosteric modulators of MOPr, particu-
larly positive allosteric modulators (PAMs) that enhance the
activity of orthosteric MOPr agonists. PAMs of MOPr have the
potential to enhance the effects of endogenously released
opioids or low doses of opioid orthosteric agonists. The
authors speculate on the potential advantages that a PAM
approach might bring to the design of novel therapeutics for
pain that may avoid the side effects currently associated with
opioid therapy. The further development of PAMs and biased
PAMs has great potential to contribute to pain therapy,
perhaps in ways that have not been considered previously.
Analgesics such as tramadol and more recently tapentadol
exploit therapeutic interactions between opioid and other
neurotransmitter systems. Synergistic interactions improve
the therapeutic profile of opioids by limiting the degree
of stimulus of the opioid system required to produce pain
relief. Chabot-Doré et al. (2015) comprehensively review
evidence for the best established interactions between
α2-noradrenergic agonists and both MOPr, and DOPr to
provide pain relief in animal models. Sadeghi et al. (2015)
describe additive mechanisms underlying the action of tap-
entadol in brain neurons.
Development of tolerance is one of the major limitations
of long-term opioid treatment. Understanding the mecha-
nisms of MOPr regulation is thought to be crucial for under-
standing and potentially developing strategies to limit
tolerance. Coordinated phosphorylation of C-terminal serine
and threonine residues on MOPr plays a crucial role in the
initial steps and perhaps sustained mechanisms of MOPr
regulation, arrestin binding and endocytosis. Stefan Schulz’s
group review their pioneering work (Mann et al., 2015) on
the development and use of phospho-site specific antibodies
to study homologous and heterologous MOPr regulation, the
latter mediated by protein kinase C phosphorylation of
MOPr. This could provide an explanation for the protein
kinase C (PKC)-mediated desensitization of MOPr by mor-
phine, when PKC has been activated, as observed in a range
of cells (Henderson, 2015). However, the research paper of
Arttamangkul et al. (2015) suggests the effects of PKC-
inhibitors on MOPr may be indirect. Understanding the rel-
evance of different phosphorylation sites and regulation of
MOPr is very important because many splice variants and
some of the polymorphisms of human MOPr involve this
region of the receptor with potential implications for sensi-
tivity to opioid analgesics, tolerance and addiction. Knapman
and Connor (2015) comprehensively review the evidence for
functional implications of human MOPr polymorphisms and
a research paper in the themed issue (Cooke et al., 2015)
examines the effects of one of these polymorphisms, L83I, on
MOPr endocytosis in detail. Several of the submitted research
papers in the themed issue further address mechanisms of
MOPr regulation after chronic treatment with morphine (e.g.
Connor et al., 2015; Macey et al., 2015). The research paper
by Lowe and Bailey (2015) adds to the evidence that the
mechanisms of MOPr desensitization in nerve terminals
differ from those in the soma.
The important role of the DOPr in mechanisms of toler-
ance and dependence to MOPr agonists and addiction related
mechanisms is discussed in a number of papers that highlight
the as yet unrealised therapeutic potential of DOPr drugs for
addiction management. Comprehensive review and research
papers by Laurent et al. (2015a,b) comment on the role of
forebrain MOPr and particularly DOPr in reward and decision
making. The main finding that long-term translocation of
DOPr to the surface of cholinergic interneurons in the
nucleus accumbens shell is associated with the selection and
execution of goal-directed actions is particularly interesting
although the cellular and molecular mechanisms involved
are not yet understood. The review by Klenowski et al. (2015)
comprehensively addresses the role of DOPr in addiction to a
range of drugs. Baimel et al. (2015) discusses the interactions
between the orexin/hypocretin system and opioids in brain
regions related to addiction and potential for modulation
addiction to opioids and other drugs.
Therapeutic actions and adverse effects of opioids are not
limited to analgesia or other nervous system actions. Reviews
and research papers arising from the INRC symposium on
‘Opioids in Non-Neuronal Cells’ provide a perspective
on actions not often considered by those working in the
CNS. There is considerable interest and some controversy
concerning the influence of opioid therapeutics on tumour
progression. Yamamizu et al. (2015) discuss evidence and
mechanisms whereby opioid κ-receptor (KOPr) agonists are
anti-angiogenic so may have tumour suppressing properties.
Morphine is commonly used in cancer pain management but
there have been concerns that the drug may adversely influ-
ence post-operative cancer recurrence and metastasis.
Afsharimani et al. (2015) provide a critical review of the valid-
ity of animal models designed to evaluate the effect of mor-
phine on tumour growth and metastasis and suggest ways to
improve current approaches. Another noteworthy action of
opioids on non-neuronal cells includes the influence of DOPr
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receptor agonists on cutaneous wound healing (Bigliardi
et al., 2015).
Ultimately, the value of much of the knowledge of novel
opioid mechanisms in the themed issue will be its translation
into clinical practice. Avoiding tolerance and dependence,
severe side effects and improving efficacy in chronic pain
conditions all seem possible but there is a long way to go. For
example, careful meta-analyses of weak and strong opioid use
in chronic non-cancer pain (Reinecke et al., 2015) found only
modest trends for efficacy of opioids and no evidence to
support the sole or preferential use of opioids. Hopefully
drugs exploiting novel opioid mechanisms will be better.
Opioid agonists and antagonists also have an important place
in management of addictions. For reviews of opioid treat-
ments for addiction in humans the reader is referred to the
recent issue of British Journal of Clinical Pharmacology on
Addiction (2014, vol 77, Issue 2. Pp 225–400). In particular,
articles by Bell (2014) and Garcia-Portilla et al. (2015) on
maintenance treatments for opioid addiction and sustained
release naltrexone for the management of opioid dependence
(Kunøe et al., 2014).
Current opioid therapeutics for chronic pain manage-
ment and addiction are problematic and still largely rely on
drugs developed many decades ago. There is hope that find-
ings in this themed issue will lead to the development of new
generation opioid analgesics with improved clinical profiles.
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